The August 2026 lawsuits against sellers
On August 12, 2026 Lilly announced six new lawsuits against U.S. businesses selling what it called black-market retatrutide. The defendants are compounding pharmacies, medical spas and online sellers that label their products "research-use only".[1]
| Federal court | State |
|---|---|
| U.S. District Court, Northern District of California | California |
| U.S. District Court, Western District of Texas | Texas |
| U.S. District Court, Eastern District of Texas | Texas |
| U.S. District Court, Southern District of Texas | Texas |
The defendants are named in Lilly's release. This site does not repeat seller names, in line with our editorial policy.
Lilly also reported wider action alongside the lawsuits:[1]
- More than 200 individuals and entities referred to the FDA, the Department of Justice, state attorneys general, law enforcement and professional licensing boards.
- More than 14,000 websites, advertisements, social media posts and product listings reported to internet providers and platforms, across more than 100 countries.
Lilly's chief medical officer, David Hyman, said: "What is being sold on the black market is not a medicine."[1]
What Lilly asked others to do
The same announcement called on several groups to act:[1]
| Group | Request |
|---|---|
| Regulators, customs and law enforcement | Treat unapproved retatrutide sales as an urgent public health problem and coordinate across borders |
| Social media and e-commerce platforms | Block listings before they reach consumers |
| Payment, shipping and logistics companies | Stop providing services to sellers |
| Health care providers | Raise awareness of the risks |
| The public | Report illegal products to authorities or the Lilly Answers Center (1-800-LillyRx) |
Lilly v. FDA: is retatrutide a drug or a biologic?
The other retatrutide lawsuit is Lilly's own case against the FDA. On March 18, 2024, the FDA classified retatrutide as a drug rather than a biological product. Its reasoning: a "protein" must be an alpha amino acid polymer of more than 40 amino acids, and retatrutide does not meet that definition.[2]
Lilly's request described retatrutide as 41 amino acids in total: a backbone of 39 alpha amino acids plus a two-residue side chain. Lilly argued all of them should count. It sued under the Administrative Procedure Act in the Southern District of Indiana (case 1:24-cv-01503).[2]
| Date | Step |
|---|---|
| March 18, 2024 | FDA letter of designation: retatrutide is a drug, not a biological product[2] |
| 2024 | Lilly sues in the Southern District of Indiana[2] |
| September 30, 2025 | Court upholds FDA on "not a protein" but vacates and remands FDA's finding that retatrutide is not "analogous" to a protein[2] |
| 2026 | Appeal docketed in the Seventh Circuit, No. 26-1301; no appeals-court decision found as of November 13, 2026[3] |
The court noted that the FDA could still lawfully reach the same conclusion on remand.[2] The classification matters because it decides whether retatrutide is licensed as a biologic or approved as a drug, which changes the approval pathway and the rules for later competitors. Lilly has said it plans to submit a biologics license application in the first quarter of 2027.[11]
FDA enforcement actions on retatrutide
The FDA's position is direct: "retatrutide and cagrilintide cannot be used in compounding under federal law," and it has warned telehealth firms, ingredient distributors and outsourcing facilities over retatrutide.[4] Warning letters that named retatrutide include:
| Date | Type of recipient | FDA finding |
|---|---|---|
| Dec 10, 2024[5] | Research-peptide sellers | Sold unapproved GLP-1 drugs, including retatrutide |
| Sep 9, 2025[6] | Compounder | Retatrutide fails compounding conditions; there are "no FDA-approved applications" |
| Mar 31, 2026[7] | Online peptide seller | Retatrutide sold as a "GLP-1-R peptide" labeled "Research Use Only" |
| Aug 24, 2026[8] | Online peptide seller | Selling bacteriostatic water with a "peptide guide" and "peptide calculator" showed intended human use |
At the border, the FDA's September 2025 "green list" import alert is meant to stop unapproved GLP-1 ingredients from entering the country.[9]
What this means if you are looking for retatrutide
None of these cases changes the basic fact: retatrutide is not approved, and Lilly says anyone selling it to consumers is breaking the law.[10] The legal routes are a clinical trial or a doctor's expanded-access request, explained on how to get retatrutide and Eli Lilly retatrutide early access. The risks of online products are covered on retatrutide peptide sold online.
Frequently asked questions
Who did Eli Lilly sue over retatrutide?
Six U.S. businesses, announced on August 12, 2026: compounding pharmacies, medical spas and online sellers marketing "research-use only" retatrutide. The cases were filed in federal courts in California and Texas.[1]
Why is Eli Lilly suing the FDA over retatrutide?
Has the FDA taken enforcement action against retatrutide sellers?
What is the retatrutide black market?
Lilly's term for sales of unapproved retatrutide by compounding pharmacies, medical spas and online "research-use only" sellers. Lilly says it has reported more than 14,000 listings in over 100 countries.[1]
Sources
- Lilly calls on online platforms, payment companies and regulators to shut down the illegal retatrutide black market
- Eli Lilly and Company v. Kennedy, No. 1:24-cv-01503-TWP-KMB, order on cross-motions for summary judgment
- Eli Lilly and Company v. Robert Kennedy, Jr., et al., No. 26-1301
- FDA's concerns with unapproved GLP-1 drugs used for weight loss
- Warning letter: Summit Research Peptides
- Warning letter: GLP-1 Solution
- Warning letter: Gram Peptides
- Warning letter: Royal Peptides LLC
- FDA launches "green list" to protect Americans from illegal imported GLP-1 drug ingredients
- Lilly: retatrutide vs semaglutide 2 mg in TRANSCEND-T2D-2
- Lilly: retatrutide successful in two additional phase 3 obesity trials (TRIUMPH-2, TRIUMPH-3)